What does an equity research analyst actually do?

Behind those two outputs sits a stack of financial models, channel checks, expert calls, and rewritten memos that very few readers ever see. In our work translating raw data into screening frameworks, we treat the equity research function as the upstream signal generator for almost every active-investment decision. So it is worth unpacking what these analysts actually do, where their incentives bend, and why the regulatory environment has quietly rewritten their workflow.

The Core Mandate: From Financial Statements to a Single Rating

The output of an equity research analyst is, at first glance, deceptively simple. Every report culminates in a recommendation — buy, sell, or hold — and a target price. Everything upstream is justification.

The core mandate breaks into five recurring tasks:

• Financial statement analysis — parsing 10-Ks, 10-Qs, and annual reports to model revenue growth, margin trajectories, and capital allocation decisions.
• Forecasting and modeling — building and updating discounted cash flow (DCF) models, comparable company analyses, and sum-of-the-parts frameworks in Excel.
• Primary research — running "channel checks" (talking to suppliers, customers, and distributors) and expert calls to validate or contradict the consensus view.
• Report writing — translating the model output and field intelligence into a published note that portfolio managers can act on.
• Issuing ratings and price targets — the compressed output that drives capital flows.

The software stack behind these tasks is fairly standardized. Bloomberg Terminal, FactSet, S&P Capital IQ, and Refinitiv Workspace (the rebranded Thomson Reuters Eikon) handle data ingestion and historical multiples; Excel is where the custom modeling lives. Every DCF or comps table a published analyst references has been rebuilt, sensitivity-tested, and rebuilt again by an associate before it reaches a reader's screen.

The rating is the headline. The model is the actual product.

Sell-Side vs. Buy-Side: Same Skill Set, Different Incentive Function

If you only ever read sell-side reports, you will systematically misunderstand how equity research works. The profession is bifurcated along an incentive boundary that most retail readers never see.

Sell-side analysts work for investment banks and brokerages. They publish research externally, and the implicit goal is to generate trading commissions. Their audience is broad, their reports are public, and their reputation hinges on being right often enough that institutional clients keep order flow routed through their desk.

Buy-side analysts work for asset managers, hedge funds, or pension funds. Their research is internal. The output is not a published rating but an investment decision inside a portfolio. Compensation here is tied directly to portfolio performance, which structurally tightens the feedback loop between a wrong call and a consequence.

The distinction matters because the same headline rating ("Buy, $180 target") carries a different signal in each context. A sell-side buy carries the weight of an attempt to influence order flow; a buy-side buy, if you ever get to see it, is closer to a position already sized.

The Daily Grind: Modeling, Calls, and the Earnings-Season Spike

The workflow outside of earnings season is steady but demanding — typically 50 to 70 hours per week, with daily shifts around 12 hours. A typical day clusters around three blocks: morning data and price-action review, mid-morning to mid-afternoon model updates or primary research, and late-afternoon report drafting.

Earnings season compresses everything. During the four quarterly reporting windows, daily shifts run 16 hours or longer and weekly totals can reach 70 to 80-plus hours. Every covered company prints numbers in a tight window, every model needs to be re-run within hours of the release, and every published rating is at risk of being invalidated before the ink dries.

A rough allocation of a typical non-earnings-season week tends to look something like this:

• Modeling and Excel maintenance — the largest single block, roughly a third of the week.
• Primary research — channel checks, expert calls, supplier conversations.
• Report drafting and editing — turning model output into a publishable note.
• Client or PM communication — fielding questions, presenting calls.
• Data ingestion and corporate-access events — conferences, non-deal roadshows, management meetings.

These proportions shift sharply during earnings season. The modeling block balloons because every covered name has just printed; the report-drafting block expands because rating updates need to ship within hours, not days; the primary-research block often contracts because there is no time to call anyone.

Regulatory Shifts: How MiFID II Rewrote the European Coverage Map

The largest structural disruption to the equity research function in the last decade was not algorithmic trading, AI, or data costs — it was a European regulation. MiFID II went live on January 3, 2018, and its "unbundling" provision forced asset managers to pay separately for research rather than folding the cost into trade-execution commissions. Money moved into either the firm's own P&L or a segregated Research Payment Account.

The intent was to surface the true cost of research and let asset managers negotiate. The empirical result was a contraction of sell-side coverage across European equities:

• 5.3% decrease in sell-side coverage of European companies post-MiFID II.
• 11.6% decrease in analyst employment at European brokerages.
• 12.4% decline in stock market liquidity for affected companies.

Small and medium-sized enterprises absorbed most of the damage. Coverage has been rationalized toward liquid large caps where the research budget is recoverable through commission flow, leaving a coverage desert across much of the European SME space.

The regulatory response came on December 4, 2024, when the EU Listing Act took effect. It softened the unbundling rules by removing the previous €1 billion market-cap threshold for SME exemptions and allowing joint payments for research and execution under specific conditions. The stated goal is to restore some SME coverage; whether that goal is actually achieved will be visible in the next two to three years of coverage data.

The absence of a sell-side note on a name is not always a signal of low quality. Sometimes it is just a function of the regulation making the coverage uneconomic.

For self-directed investors reading European research, this matters. If a small-cap European name has zero analyst coverage, the explanation may be structural rather than informational.

Compensation and Career Progression

The career path inside equity research is fairly linear at the analyst and associate levels, with the bifurcation between research management and portfolio management typically happening at the VP-to-Director transition.

Total compensation bands, anchored to major U.S. and European financial centers:

• Research Associate / Senior Associate: $125,000–$200,000 total, with base salary typically 75% or more of the package.
• Vice President (Senior Analyst): $200,000–$300,000, base share still around 75%.
• Director: $300,000–$600,000, with the variable component starting to dominate.
• Managing Director: $500,000–$1,000,000.
• Top Institutional Investor-ranked analyst: $1.0–$2.5 million.

Buy-side packages are structured differently. Base salary is a smaller share, and the variable is tied to portfolio performance. A buy-side analyst who consistently generates alpha will out-earn a sell-side peer of equivalent rank; a buy-side analyst whose book underperforms will be out the door quickly. The feedback mechanism is faster, which is precisely why some sell-side analysts transition buy-side and never come back.

A Checklist for Reading Analyst Output

If you are a self-directed investor using published research, we suggest filtering every note through the same parameters we apply to our screening models. Run each report through this checklist before letting the rating move your position:

• Identify the side. Sell-side or buy-side — the rating carries a different signal in each context.
• Inspect the model, not just the conclusion. If the note publishes a target price but no DCF or comps table, the target is a guess with a confident wrapper.
• Cross-check the target against consensus. A target materially above or below consensus should come with explicit assumptions you can stress-test.
• Confirm the coverage history. A freshly initiated rating is worth less than a reaffirmed rating from an analyst who has covered the name across multiple cycles.
• Look for primary-research signals. Mentions of channel checks, expert calls, or supplier interviews indicate the analyst is doing work, not just aggregating consensus.
• Note the timing relative to earnings. A rating updated inside the 48 hours after an earnings print is reacting to information; a rating updated two months before earnings is positioning ahead of it.
• Check for conflicts. Underwriting relationships, IPO allocation, and investment-banking mandates all bias sell-side output, even when the analyst is honest.

Equity research, when it is done well, is a structured translation of public and primary data into a probability-weighted judgment about future cash flows. When it is done badly, it is a marketing document with a price target on the front page. The work of reading it well is to know which one you are holding.